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Background: High risk prescribing can compromise independent wellbeing and quality of life in older adults. The
aims of this project are to determine the prevalence, risk factors, clinical consequences, and costs of high risk
prescribing, and to assess the impact of interventions on high risk prescribing in older people.
Methods: The proposed project will utilise data from the 45 and Up Study, a large scale cohort of 267,153 men
and women aged 45 and over recruited during 2006–2009 from the state of New South Wales, Australia linked to a
range of administrative health datasets. High risk prescribing will be assessed using three indicators: polypharmacy
(use of five or more medicines); Beers Criteria (an explicit measure of potentially inappropriate medication use); and
Drug Burden Index (a pharmacologic dose-dependent measure of cumulative exposure to anticholinergic and
sedative medicines). Individual risk factors from the 45 and Up Study questionnaire, and health system
characteristics from health datasets that are associated with the likelihood of high risk prescribing will be identified.
The main outcome measures will include hospitalisation (first admission to hospital, total days in hospital,
cause-specific hospitalisation); admission to institutionalised care; all-cause mortality, and, where possible,
cause-specific mortality. Economic costs to the health care system and implications of high risk prescribing will be
also investigated. In addition, changes in high risk prescribing will be evaluated in relation to certain routine
medicines-related interventions. The statistical analysis will be conducted using standard pharmaco-epidemiological
methods including descriptive analysis, univariate and multivariate regression analysis, controlling for relevant
confounding factors, using a number of different approaches.
Discussion: The availability of large-scale data is useful to identify opportunities for improving prescribing, and
health in older adults. The size of the 45 and Up Study, along with linkage to health databases provides an
important opportunity to investigate the relationship between high risk prescribing and adverse outcomes in a
real-world population of older adults.
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In older adults, high risk prescribing can be defined as
prescribing likely to lead to adverse clinical outcomes or
prescribing that does not align with quality use of medi-
cines principles. A range of indicators have been proposed
to quantify high risk prescribing in older people. These in-
clude multiple medication use or polypharmacy, poten-
tially inappropriate prescribing and exposure to high risk
medicines, measured using different risk assessment tools.
Although the concomitant use of multiple medicines
is often indicated in the treatment and prevention of
health problems, polypharmacy is generally considered
as high risk prescribing in older adults, and is associated
with increased risk of harm [1-3], including adverse drug
reactions, falls, hospitalisation, institutionalisation, and
mortality [1]. Polypharmacy (concomitant use of ≥ 5 medi-
cines) is common in older adults, and is estimated to be
present in around half of Australians aged 65–74 years,
and two-thirds of those aged ≥75 years [4]. The prevalence
of “hyperpolypharmacy” (concomitant use of ≥ 10 medi-
cines) in community-dwelling older adults has been
reported to range from 5% to 26% [5,6].
High risk prescribing also includes potentially inappro-
priate prescribing, defined as the use of medicines whose
potential harms to older adults may outweigh the benefits
[7]. Potentially inappropriate prescribing can be assessed
using explicit and implicit approaches. The Beers Criteria,
an explicit USA consensus list is the most widely used in-
dicator to define potentially inappropriate prescribing
[7,8]. The associations between Beers Criteria and out-
comes have been investigated across a range of popula-
tions and settings of older adults, with mixed findings
being reported across studies [9]. Despite the efforts to
improve the quality use of medicines in this population,
recent systematic review suggests that potentially inappro-
priate prescribing is still common in older people [10].
High risk prescribing may also encompass exposure to
“high-risk” medicines such as those with anticholinergic
and sedative properties. A number of anticholinergic and/
or sedative scores have been developed to capture the
cumulative exposure to these pharmacological classes [2].
One such tool is the Drug Burden Index (DBI), a pharma-
cological score based on the principles of dose–response
and cumulative effect, that measures an individual’s total
exposure to medicines with anticholinergic and sedative
effects [11]. In studies of older people, the prevalence of
exposure to DBI medicines ranged from 29–70% [12,13].
Increasing DBI score has been associated with a higher
risk of a range of adverse clinical outcomes, including
functional impairment, frailty, falls and hospitalisation in
populations of older adults from the USA, Australia and
Europe [11-19].
Strategies to reduce high risk prescribing, including
pharmacist-conducted medication reviews, educationalinterventions and policy approaches, have been trialled
in older adults [20-22]. However, the success of these
interventions has been limited. To reduce the likelihood
of clinically significant adverse outcomes, rational with-
drawal of medications may be the appropriate clinical
decision and may result in significant clinical benefits in
some older people with high risk prescribing [23]. To
date, real-world approaches to reduce polypharmacy in
older people have generally not been successful [22,24].
While interventional approaches can reduce medication
exposure in older adults, the evidence for their clinical
effectiveness and sustainability is conflicting [24].
The current evidence from pharmaco-epidemiological
studies suggests that high risk prescribing increases the
risk of adverse outcomes in older adults [1,2]. However,
there is a lack of reliable evidence at the population level
on the prevalence and outcomes relating to high risk
prescribing in older people. Moreover, evidence is re-
quired regarding the impact of pragmatic medicines-
related interventions aimed at improving medication
management in older adults. The aims of this project are
to determine the prevalence, risk factors, clinical impli-
cations and costs of high risk prescribing, and the im-
pact of interventions on high risk prescribing in older
people within a large population-based cohort study;
specifically to:
1) Estimate the prevalence of high risk prescribing;
2) Investigate the risk factors for high risk prescribing;
3) Quantify the relationship of high risk prescribing to
adverse health outcomes;
4) Determine whether associations between high risk
prescribing and adverse outcomes vary according to
individual and/or health care system specific factors;
5) Calculate the economic cost and implications of high
risk prescribing to the health care system;
6) Investigate whether certain routine medicines-related
interventions, including the Home Medicines Review
and Chronic Disease Management are associated
with reductions in high risk prescribing.
Methods
Overview of data sources
The proposed cohort analysis will utilise a population-
based dataset combining self-reported questionnaire
data (including data on life-style and social factors, func-
tional capacity, physical activity, medical diagnosis and
medication data) linked to routine administrative health
datasets. This project will utilise the following data sources:
the 45 and Up Study baseline questionnaire; the Australian
Commonwealth Medicare Benefit Scheme (MBS) claims
data, Pharmaceutical Benefit Scheme (PBS) claims data,
Aged and Community Care Management Information
System (ACCMIS) database, National Death Index; and
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Patients Data Collection (APDC), and the Register of
Births, Deaths and Marriages (Figure 1).
The 45 and Up study cohort
The 45 and Up Study cohort includes 267,153 men and
women aged 45 and over from the state of NSW, Australia,
randomly sampled from the Medicare Australia database
[25]. Participants completed a self-administered postal
questionnaire and provided signed consent for participa-
tion and follow-up, including linkage to health records (in-
cluding data on deaths, hospital admissions, and aged care
admissions). Recruitment was conducted from February
2006 to April 2009, with an 18% response rate. Following
exclusion of individuals with missing data on age and sex,
266,074 participants remained. Of these, 143,199 (54%) are
aged 60 years and over (Table 1). Overall, 28% (n = 73,528)
of the cohort reported holding a healthcare concession
card, hereafter referred as concession card holders. This
status will also be confirmed using the health administra-
tive databases. For the purposes of the High Risk Prescrib-
ing project, the study sample will be restricted to cohort
members who are concession card holders, as this allows
full capture of health care utilisation.
Commonwealth administrative health datasets
MBS and PBS administrative databases
MBS and PBS are part of the Australia's national health
insurance arrangements [26]. These schemes provide sub-
sidised access to medical services and pharmaceuticals for
Australian residents. The MBS database contains detailed
information on Commonwealth subsidised claims for med-
ical services performed outside the public hospital in-
patient setting.
The PBS database contains information on Common-
wealth subsidised claims for prescribed medicines listed
on the Schedule of Pharmaceutical Benefits. There are
two main groups of PBS beneficiaries, concession cardMEDICATION EXPOSURE
Pharmaceutical 
Benefit Scheme (PBS) 
data restricted to 
concession card
holders
45 and Up Study
STUDY POPULATION
266, 074 NSW men 
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Figure 1 Overview of the data sources. Abbreviation: ABS, Australian Buholders and general beneficiaries. The PBS database
records only PBS-listed prescription medicines that at-
tract a government subsidy. Concession card holders
are required to contribute a co-payment of $5.80 (as at
January 1st 2012) towards the cost of their medicines.
Since all PBS medicines cost more than the concession
card holder threshold, they will always attract a Com-
monwealth subsidy. Therefore medication data from
concession card holders are captured consistently in the
PBS database. However, the co-payment threshold for
general beneficiaries is $35.40 (as at January 1st 2012).
There are a range of PBS-listed medicines that cost less
than this co-payment threshold. When these medicines
are dispensed to a general beneficiary, the general bene-
ficiary is required to pay the full cost of the medicines
and the government does not contribute to payment.
Consequently, PBS-medicines falling below the co-payment
were not captured in the PBS database for general benefi-
ciaries. However, following a policy change, since April
2012 the PBS database now captures all PBS-dispensed
medicines, regardless of whether the government contri-
butes to the payment. To manage the potential incomplete
capture of PBS-listed medicines dispensed to general bene-
ficiaries we will restrict our analysis to healthcare conces-
sion card holders. Recent estimates indicate that over 90%
of individuals aged 65 years and over hold a government
health care concession card [27]. Therefore, the results
will be highly generalisable to the general population of
older Australians.
ACCMIS, National Death Index and Australian bureau
statistics mortality data
The ACCMIS contains information on residential aged
care services provided to older people who can no longer
live at home [28]. The National Death Index dataset con-
tains records of all deaths occurring in Australia since
1980 [29], along with data from the Australian Bureau of
Statistics on cause of death.NSW Admitted 
Patients Data
Collection (APDC) 
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Table 1 Characteristics of the concession card holders in
the 45 and Up study, and total study population
Characteristic~ Concession card holders




Age groups, n (%)
45–59 years 14,888 (20%) 122,875 (46%)
60–69 years 25,599 (35%) 73,833 (28%)
70–79 years 20,432 (28%) 42,256 (16%)
≥ 80 years 12,609 (17%) 27,098 (10%)
Sex, n (%)
Male 32,755 (45%) 123,402 (46%)
Female 40,773 (55%) 142,672 (54%)
Country of birth, n (%)
Australia born 54,031 (73%) 199,342 (75%)
Born outside of Australia 19,497 (27%) 66,732 (25%)
Highest educational qualification, n (%)
University degree 7,289 (10%) 61,290 (23%)
Certificate/diploma 21,932 (30%) 84,556 (32%)
Higher school/leaving
certificate
6,757 (9%) 25,985 (10%)
School/intermediate certificate 20,338 (28%) 58, 611 (22%)
No certificate 15,358 (21%) 31,194 (12%)
Household income, n (%)
Less than $20,000 31,380 (43) 52,359 (20%)
$20,000-$39,999 17, 260 (23%) 46,555 (17%)
$40,000-$69,999 5,545 (8%) 46,968 (18%)
$70,000 or more 1,007 (1%) 62,553 (24%)
Missing 18,336 (5%) 57,639 (22%)
Marital status, n (%)
Married/defacto 46,771 (64%) 198,760 (75%)
Not married* 26,265 (36%) 65,703 (25%)
Region, n (%)
Inner regional 29,909 (38%) 93,581 (35%)
Major cities 28,600 (39%) 119,792 (45%)
More remote 17,008 (23%) 52,640 (20%)
Lifestyle and social factors
Alcohol use, number of drinks per week, n (%)
None 31,163 (42%) 86,198 (32%)
1–14 31,400 (43%) 136,880 (51%)
≥ 15 8,517 (12%) 37,357 (14%)
Smoking history, n (%)
Current smoker 6,833 (9%) 19,247 (7%)
Former smoker 28,365 (39%) 96,080 (36%)
Never-smoker 38,017 (52%) 149,900 (56%)
Body Mass Index, kg/m2, n (%)#
Underweight (15–18.4 kg/m2), 1,139 (2%) 3,094 (1%)
Table 1 Characteristics of the concession card holders in




23,306 (32%) 90,563 (34%)
Overweight
(25.0–29.9 kg/m2)
25,624 (35%) 97,163 (37%)
Obese (≥30.0 kg/m2) 16,761 (23%) 54,903 (21%)
Missing 6,698 (9%) 20, 351 (8%)
Functional capacity and medical diseases
Needing assistance with daily tasks because of long-term illness
or disability, n (%)
Yes 8,113 (11%) 14,499 (5%)
No 60,529 (82%) 238,661 (90%)
Missing 4,886 (7%) 12,914 (5%)
Physical activity, tertile, n (%)
1 22,087 (30%) 77,019 (29%)
2 23,422 (32%) 86,501 (33%)
3 21,986 (30%) 87,411 (33%)
Missing 6,033 (8%) 15,143 (6%)
Self-rated health, n (%)
Excellent 5,705 (8%) 38,758 (15%)
Very good 20,449 (28%) 94,776 (36%)
Good 26,822 (36%) 86,711 (33%)
Fair 13,864 (19%) 30,822 (12%)
Poor 3,187 (4%) 5,625 (2%)
Missing 3,501 (5%) 9,328 (4%)
Kessler 10 score, psychological distress, n (%)
Low 42,596 (58%) 180,524 (68%)
Moderate 10,223 (14%) 36,817 (14%)
High 4,623 (6%) 12,718 (5%)
Very high 2,427 (3%) 5,144 (2%)
Missing 13,659 (19%) 30,871 (12%)
Diabetes, n (%)
Yes 10,716 (85%) 24,609 (9%)
No 62,812 (5%) 241,465 (91%)
Cardiovascular diseases, n (%)^
Yes 17,157 (23%) 39, 815 (15%)
No 56,371 (77%) 226,259 (85%)
Cancer, n (%)≠
Yes 11,258 (15%) 30,426 (11%)
No 62,270 (85%) 235,648 (89%)
Missing values given where they amount to 5% or more of the total.
~ Percentages do not add up to 100% in all instances due to missing values
and rounding.
*Single, widowed or divorced.
#Body Mass Index categories in line with World Health Organization classifications.
^Heart disease, stroke or blood clot.
≠Self-reported history of cancer excluding skin cancer.
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APDC and NSW registry of births and death databases
The APDC is a complete census of all services for ad-
mitted patients provided by public hospitals, public psy-
chiatric hospitals, public multi-purpose services, private
hospitals and private day procedure centres in NSW,
Australia [30]. Finally, the NSW Registry of Births and
Death will be utilised to provide fact of death data.
Linkage process
The data linkage procedures will be performed separ-
ately for Commonwealth and NSW databases as these
health datasets are held by different jurisdictions. The
linkage processes are summarised below.
Commonwealth datasets
As 45 and Up Study participants were sampled from the
Medicare enrolment database and each was assigned an
encrypted version of the unique Medicare ID, the link-
age to PBS and MBS Commonwealth data is deter-
ministic. PBS and MBS data for all 45 and Up Study
participants have already been linked to baseline ques-
tionnaire data. The linkage with the National Death
Index dataset, including the Australian Bureau of Statis-
tics mortality data will be performed by the Australian
Institute of Health and Welfare. Linkage of the ACCMIS
database to the 45 and Up Study and other datasets
through a third party using best practice privacy preserv-
ing protocols will be explored.
NSW datasets
The Centre for Health Record Linkage (CHeReL) rou-
tinely links identifying details (including full name, date
of birth, sex and address) from 45 and Up Study partici-
pants to those from the NSW APDC and death records,
to provide regular updates to events in the cohort. This
is a part of an established program of linkage. Records
are matched probabilistically using privacy-preserving
current best practice with ChoiceMaker software [31], an
algorithm based on maximum entropy theory to develop
a predictive model that classifies record pairs.
Medication exposure
Medication exposure will be measured using the 45 and
Up Study predominantly using PBS dispensing data, vali-
dated and calibrated against self-reported medication
use from the 45 and Up Study questionnaire. As the PBS
database does not capture private prescriptions, medicines
dispensed to public hospital inpatients, over-the-counter
medicines and many complementary and alternative medi-
cines, the extent to which PBS data reliably categorise high
risk prescribing is not known. The authors are currently
conducting the validation projects to estimate the extent
and implications of any under-ascertainment of high riskprescribing using PBS data, compared with self-reported
measures from the 45 and Up baseline questionnaire.Assessment of high risk prescribing
High risk prescribing will be defined using three indica-
tors: polypharmacy; Beers Criteria; and DBI. Polyphar-
macy will be defined as the concurrent dispensing of
five or more medicines [32] over a six month period,
and using the total number of medicines as a continuous
variable. The updated 2010 Beers criteria will be used to
assess potentially inappropriate prescribing [8]. The
linked datasets will be screened for medicines and diag-
nosis considered by the updated Beers criteria. Data on
six medical conditions included in the updated Beers cri-
teria have been collected for the 45 and Up Cohort. Medi-
cines will be used as a surrogate marker of other diseases
considered by the updated Beers criteria [15]. Inappropri-
ate prescribing will be considered present if the partici-
pant is prescribed at least one medicine included in the
updated Beers criteria.
The DBI, a measure of exposure to drugs with anti-




D= δ þ Dð Þ½ ;
where D is the daily dose, and δ is the minimum effica-
cious dose (the minimum dose in the approved product
information registered by the Australia’s Therapeutic Goods
Administration, TGA), an estimate of the dose required to
obtain 50% of the maximal effect. The daily dose will be
estimated from the total quantity dispensed, using a stand-
ard pharmaco-epidemiological approach [33], by multiply-
ing the strength (mg) and quantity dispensed, divided by
the time period over which the medicines were taken dur-
ing the study period. The total drug burden for the partici-
pant will be calculated as the sum of the drug burden of
all anticholinergic or sedative medicines a participant is
exposed to using a linear additive model. The Anatomical
Therapeutic Codes (ATC) will be used to screen for anti-
cholinergic and sedative drugs [34]. The minimum dose
registered by the TGA will be obtained for all drugs with
anticholinergic and sedative effects.Risk factors
Data on individual risk factors from the 45 and Up Study
questionnaire (eg. age, gender, socioeconomic status, dis-
ability), and health system characteristics from linked data
(eg. prescriber, number of pharmacies and geographical
region) will be obtained to identify factors associated with
the likelihood of high risk prescribing.
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Data on a range of clinical outcomes will be obtained, in-
cluding: hospitalisation (first admission to hospital, total
days in hospital, cause-specific hospitalisation, covering
falls-related hospital admission, and fracture-related hos-
pital admission); all-cause mortality; and, where possible,
admission to institutionalised care and cause-specific mor-
tality. Follow-up will be from the date of recruitment, to
the last available data on hospitalisation, death or institu-
tionalisation, whichever occurs first. The 45 and Up Study
recruitment was from February 2006 to April 2009, giving
a range of follow-up duration of 2–5 years, by end 2012
(accounting for linked data delays).
Health interventions
Changes in high risk prescribing will be evaluated in re-
lation to two health interventions: the Home Medicines
Review [35], and the Chronic Disease Management [36]
item of the MBS. The Home Medicines Review is a
Commonwealth-funded service introduced in 2001. It is
a free collaborative medication management service pro-
vided to the patient. The collaborative service involves
the patient, their primary physician and pharmacist,
whereby the pharmacist referred by the patient’s general
practitioner conducts an interview with the patient and
generates a written report for the primary physician to
discuss the medication management plan with their pa-
tient. The Chronic Disease Management program was
introduced in 2005 to enable primary care physicians to
plan and coordinate the health care of patients with
chronic or terminal medical conditions. A ‘chronic med-
ical condition’ is one that has been or is likely to be
present for at least six months, including but not limited
to asthma, cancer, cardiovascular disease, diabetes melli-
tus, musculoskeletal conditions and stroke.
Economic analysis
The cost analysis will be undertaken from a health sys-
tem perspective. Total annual health system costs will be
estimated overall and for each type of health care re-
source utilisation for each individual in the 45 and Up
Cohort, based on their hospital, Medicare and pharma-
ceutical utilisation data. Costs will be assigned to each
type of resource utilisation based on standard Australian
sources (for example, using the PBS and MBS for pharma-
ceutical and medical services, national Australian Refined
Diagnosis Related Groups cost weights for inpatient ser-
vices and standard ambulatory costs for outpatient and
emergency department visits). Differences in total and
average annual costs will be estimated for the high-risk and
non-high risk prescribing groups using each of the defini-
tions of high risk prescribing. Covariates will be included
in the cost equations and interacted with a dummy variable
for the high risk prescribing group. Differences in totalhealth care costs and for each type of health care resource
utilisation will be estimated.
Statistical analysis
The statistical analysis will be conducted using the
standard pharmaco-epidemiological methods including
descriptive analysis, univariate and multivariate regres-
sion analysis (eg. Cox regression modelling, negative bi-
nomial or Poisson regression), time-varying methods,
and controlling for relevant confounding factors using a
number of different approaches (eg. stratification by dis-
ease, propensity scores modelling).
To answer the first study objective, analysis will be
performed to calculate the high risk prescribing indica-
tors, using the 45 and Up Study cohort, linked to PBS
data and restricted to concession card holders. The pat-
terns of high risk prescribing will be summarised using
proportions and means. To answer the second and third
objectives, analysis will be performed to identify individ-
ual and health system based risk factors for high risk
prescribing, using the same dataset in aim one. Univari-
ate and multivariate analysis with relevant covariates will
be used to quantify the risk for high risk prescribing
compared to age and gender-matched controls. Using
the same dataset, linked to other data sources, we will
investigate the relationship of high risk prescribing indi-
cators with hospitalisations, deaths and institutionalisa-
tion, allowing for a range of factors. Analysis related to
the fourth objective – calculation of the economic costs
and implications of high risk prescribing to the health
care system – will be performed as outlined in the previ-
ous section. To answer the fifth objective, we will perform
the analysis to evaluate the possible impact of policy-
related interventions on high risk prescribing. In particu-
lar, we will compare the rates of high risk prescribing in
participants with and without these interventions and the
incidence of high risk prescribing before and after each of
these interventions, within individuals.
Sample size
Using data available to the end of 2012, the project will
be highly powered for the main outcomes, with the abil-
ity to detect a minimum relative risk of death (the least
common outcome) of 1.12, for each of the three high
risk prescribing indices (assuming the following preva-
lences: DBI 48%; Beers 20% and polypharmacy 30%)
[5,15], at 5% significance and 80% power. The incidence
of total hospitalisation and hospitalisation for falls and
fractures will be greater than the incidence of death, and
hospitalisation for adverse drug reactions is similar to the
incidence of death. To investigate the relationship between
MBS interventions and outcomes, the linkage will be
updated annually to increase power. An estimated 5% of
people aged ≥ 65 have had a Home Medicines Review;
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review items. Assuming 5% exposure over the study period,
for the smallest high risk prescribing stratum (Beers: 20%)
this would allow detection of a relative change in preva-
lence of 0.05, comparing before and after the intervention.
Ethical considerations
This study has been approved by the NSW Population
and Health Services Research Ethics Committee (approval
no. 00410). In addition, the 45 and Up Study also has
overarching in principle ethical approval for data linkage
from the University of New South Wales Human Research
Ethics Committee (approval no. 05035), Sydney, Australia
and the Department of Health and Ageing, Ethics Com-
mittee (approval no. 1/2005).
Study cohort characteristics
The baseline characteristics of the 45 and Up study par-
ticipants, and concession card holders are presented in
Table 1. In this sample, 54% were female, 75% of partici-
pants were born in Australia and 75% were married or
in a de facto relationship. In relation to lifestyle and so-
cial factors, 32% reported less than weekly alcohol use
and 7% were current smokers. Of the total population,
37% were classified as overweight and 21% as obese. Ex-
cellent self-reported health was reported by the 15% of
the population, and 68% had low psychological distress.
In the 45 and Up Study cohort, concession card holders
were generally older, had fewer educational qualifications,
were more likely to be overseas born and not married,
compared to other cohort members. In terms of func-
tional capacity, concession card holders were more likely
than non-card holders to report having a major disability,
fair or poor self-reported health status, very high psycho-
logical distress and comorbidities.
Discussion
High risk prescribing is a term used to describe a pattern
of prescribing, which, for theoretical or empirical rea-
sons, has been linked with adverse outcomes in older
people. Identifying strategies to minimise high risk pre-
scribing in older people requires a reliable evidence base
on the magnitude of the problem and the relationship of
high risk prescribing to adverse health outcomes, as well
as the effectiveness of routine interventions to improve
quality use of medicines. The Australian health system is
well suited to this, because of a rich collection of large
population-based and administrative databases. The size
of the 45 and Up Study, along with linkage to routine
health data will allow investigation of the relationship
between high risk prescribing and adverse outcomes at
the population level, including exploration of confound-
ing, effect modification and intervention effects. In
addition, opportunities to utilise other population-baseddatasets, including general PBS population and Depart-
ment of Veteran Affairs’ data will also be explored.
It should be noted that the administrative datasets are
not collected specifically to describe patterns of medi-
cine utilisation or medical care and there are some im-
portant limitations to this cohort analysis, including
generalisability, validity of data, bias and causality issues.
Cohort studies often involve selected groups and pro-
duce results based on internal comparisons within the
cohort. Theoretical and empirical work have shown these
internal comparisons to be valid and reliable [37,38], in-
cluding research from the 45 and Up Study [39]. The dur-
ability of findings from cohorts such as the British
Doctors’ Study [40] is further testament to the robustness
of this approach. The 45 and Up Study is not designed to
be representative of the general population and the re-
sponse rate to the baseline questionnaire was 18%, mean-
ing that although relative risks calculated from internal
comparisons, such as outcomes in relation to different cat-
egories of high risk prescribing, are valid and robust, cau-
tion should be exercised when generalising from the
individual prevalences of exposure and other cohort attri-
butes. Furthermore, variables from the 45 and Up Study
questionnaire are self-reported and vary in their validity.
However, the utilisation of established questionnaire in-
struments and population-level measures may minimise
the possibility of bias [25].
While the gold standard for evaluating the causal
effects of medicines on clinical outcomes is the rando-
mised controlled trial, randomising older individuals to
high risk prescribing would be inappropriate. Therefore,
observational studies are essential to elucidate the asso-
ciation between high risk prescribing and health out-
comes in this population, and to ensure the necessary
degree of heterogeneity. However, the quantification of
causality requires judicious interpretation of observa-
tional data [2]. A central issue is confounding, particu-
larly by indication, in that individuals with high risk
prescribing are likely to differ from others in ways that
will affect disease risk. Awareness of this issue, along
with using multiple analytic approaches to quantify po-
tential biases is essential, particularly to examine the ro-
bustness of the findings with different assumptions and
methods. Finally, it is important to avoid the assumption
that any observed relationship of high risk prescribing to
adverse outcomes is necessarily causal; a key focus of the
project is to quantify variation in outcomes according to
different patterns of medicines use, from the point of view
of disease burden and consequences for the health system,
rather than from a direct aetiological perspective.
In summary, the 45 and Up Study and its linkage with
health databases will allow investigation of the relation-
ship between high risk prescribing and adverse outcomes
at the population level, which has not been possible in
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unique dataset for the quality use of medicines and will
allow the identification of targets for improving prescrib-
ing in older people.
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